Drug Profile
Monoclonal antibody 323A3
Alternative Names: 323A3; Monoclonal antibody 323-A3Latest Information Update: 18 May 2010
Price :
$50
*
At a glance
- Originator Centocor
- Developer Centocor; Nonindustrial source
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Epithelial cell adhesion molecule inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Cancer
Most Recent Events
- 18 May 2010 Discontinued - Phase-I for Breast cancer in USA (unspecified route)
- 18 May 2010 Discontinued - Preclinical for Cancer in Netherlands (unspecified route)
- 18 Oct 1999 Centocor is now a wholly owned subsidiary of Johnson & Johnson